Tag:

RHPI:MEDTECH

Business

Roche Challenges Illumina with New Axelios Gene Sequencer

by Chief Editor
written by Chief Editor

Roche has launched its Axelios gene sequencer, a new platform designed to perform large-scale DNA and RNA analysis, marking the company’s attempt to compete with industry leader Illumina. Roche aims to sell about 100 machines within the first year, targeting academic and research institutions to build a foundation for long-term growth in the $7.3 billion sequencing market.

How does the Axelios platform differ from existing technology?

Unlike traditional short-read sequencing systems, the Axelios platform converts genetic material into longer molecules. These molecules are processed through tiny pores on a reusable chip to generate data in near real time. By focusing on this method, Roche aims to support applications ranging from disease research to drug development.

To ensure adoption, Roche has secured partnerships for data analysis with 10x Genomics and Google DeepVariant. Early validation for the platform has been provided by the Broad Clinical Labs and the Hartwig Medical Foundation.

Did you know?

Roche’s launch comes more than a decade after the group’s failed $6.8 billion hostile bid to acquire Illumina.

What is the market outlook for Roche’s new sequencer?

Analysts anticipate a gradual push for market share rather than a rapid disruption. Illumina currently holds approximately 70% of the next-generation sequencing (NGS) market, according to industry estimates.

What is the market outlook for Roche’s new sequencer?

Vontobel analyst Stefan Schneider stated that Roche’s target of 100 machines in the first year is achievable due to the company’s commercial scale. However, Schneider noted that diagnostic product launches often experience slower adoption rates compared to medicines because of institutional tender processes.

How do pricing models affect laboratory adoption?

Roche has priced the Axelios instrument at $750,000 in the United States. This is competitive when compared to Illumina’s NovaSeq X machines, which list between $985,000 and $1.25 million.

How do pricing models affect laboratory adoption?

Analysts note the upfront cost of the instrument is secondary to the recurring cost of supplies needed to run it, such as chemical reagents. These ongoing expenses can add up to millions of dollars over the lifespan of the machine.

Pro Tip:

When evaluating sequencing platforms, labs should prioritize the “total cost of ownership” rather than the initial hardware price, as reagent consumption often dictates the long-term budget impact of the technology.

Frequently Asked Questions

Who is the primary target audience for the Axelios sequencer?
The initial launch is restricted to academic and research-focused facilities.
What is Roche’s long-term sales goal for this platform?
The company intends to develop the Axelios into a blockbuster franchise, with the goal of generating over 1 billion Swiss francs ($1.1 billion) in annual sales over the long term.
Does the Axelios sequence DNA or RNA?
The platform is designed to handle both DNA and ribonucleic acid (RNA) by converting them into longer molecules for easier reading.

Are you involved in genomic research or laboratory procurement? Share your thoughts on the impact of new sequencing platforms in the comments below, or subscribe to our newsletter for the latest updates on biotech industry developments.

0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Approves Over-the-Counter Screwworm Treatment for Pets

by Chief Editor
written by Chief Editor

The U.S. Food and Drug Administration (FDA) has authorized the emergency use of generic nitenpyram tablets to treat New World screwworm infestations in cats and dogs. This regulatory action follows the first domestic detection of the parasite in over 60 years, with confirmed cases in cattle, a goat, and a dog across Texas and New Mexico.

What is the New World Screwworm?

The New World screwworm (Cochliomyia hominivorax) is a parasitic fly whose larvae feed on the living tissue of warm-blooded animals. According to the FDA, the parasite enters an animal’s body through open wounds, where it burrows into the flesh. If left untreated, these infestations can cause severe tissue damage and systemic infection.

From Instagram — related to Texas and New Mexico, United States
Did you know?

The New World screwworm was largely eradicated in the United States decades ago through a sterile insect technique program. The recent emergence in Texas and New Mexico marks the first domestic presence of the parasite in more than six decades.

How does the FDA-authorized treatment work?

Nitenpyram is a fast-acting oral medication now cleared under an emergency pathway to address current infestation risks. The FDA states that the drug can be administered to pets weighing at least two pounds that are at least four weeks old. Clinical evidence suggests the treatment kills most larvae within hours of the initial dose.

Veterinary guidance remains critical, however. According to the FDA, a second dose should be administered six hours after the first. The agency warns that nitenpyram does not provide residual protection against reinfestation, meaning veterinarians must often manually remove remaining larvae and provide standard wound care to ensure full recovery.

What are the risks and precautions for pet owners?

While the FDA maintains that the benefits of the treatment outweigh the potential risks, the drug is not a standalone solution for severe cases. Officials at the FDA emphasize that animals recently present in affected regions of Texas and New Mexico are at higher vulnerability, though the general risk to pets nationwide remains low.

FDA Direct — Understanding New World Screwworm w/ FDA's Vet Expert
Pro Tip:

If you suspect your pet has been exposed to the New World screwworm, contact your veterinarian immediately. Do not attempt to treat deep, burrowing wounds at home without professional medical oversight.

Future trends in veterinary parasite control

The FDA’s move to use an emergency pathway for a generic animal drug signals a shift in how federal agencies address localized disease outbreaks. By prioritizing affordable, accessible treatments, the government aims to prevent the spread of the screwworm before it reaches broader livestock populations. This strategy mirrors historical efforts to contain agricultural threats through rapid regulatory approval of existing, proven pharmaceuticals.

Future trends in veterinary parasite control

Frequently Asked Questions

  • Is this treatment available over-the-counter? Yes, the FDA authorized this generic tablet for emergency use to ensure pet owners have immediate access.
  • Can I use this for all pets? The authorization is specific to dogs and cats weighing at least two pounds and aged four weeks or older.
  • Does nitenpyram prevent future infestations? No. The FDA notes that the drug does not protect against reinfestation and should be used alongside professional veterinary care.
  • Where have the recent cases occurred? U.S. officials confirmed cases in Texas and New Mexico.

Have you checked your pet for unusual wounds recently? Share your experiences in the comments below or subscribe to our health newsletter for the latest updates on veterinary medical breakthroughs.

0 comments
0 FacebookTwitterPinterestEmail